文献速递乳腺癌

乳腺癌高风险的女性补充筛查使用对比增强乳腺摄影的前瞻性研究:患病率轮次结果

Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
PubMed 文献 · J Clin Oncol · 2024-07-26

该前瞻性单机构观察性研究纳入460名35岁及以上、常规二维数字乳腺断层摄影筛查阴性且近12个月内未接受额外补充筛查的无症状高风险女性,评估补充对比增强乳腺摄影(CEM)的筛查效果。总体补充癌症检出率为每1000人23.9例(95%CI 12.0至42.4),CEM敏感度0.917、特异度0.875。作者认为需更大规模、多机构、多年CEM试验验证。

要点

  • 高风险女性补充CEM筛查的癌症检出率为每1000人23.9例,95%CI 12.0至42.4。
  • CEM敏感度0.917(95%CI 0.760至1.000),特异度0.875(95%CI 0.844至0.906)。
  • 检出癌症均为1或2级、ER+ ERBB2-、淋巴结阴性。

核心结论

  • 试点试验显示,乳腺癌高风险女性的补充癌症检出率为每1000人23.9例。
  • 需要在高风险患者中开展更大规模、多机构、多年的CEM试验以进行验证。

研究设计与样本

  • 前瞻性、单机构、经机构审查委员会批准的观察性研究。
  • 纳入460名35岁及以上无症状高风险女性,常规二维数字乳腺断层摄影筛查阴性且近12个月内未接受额外补充筛查。
  • 研究于2019年2月至2021年4月入组,中位年龄56.8岁(范围35.0至79.2岁),408/460(88.7%)为乳腺致密型。

主要发现

  • 活检显示22名女性为良性改变(22/37,59%),4名女性为高风险病变(4/37,11%),11名女性为乳腺癌(11/37,30%)。
  • 11名女性共诊断14个癌症(10个浸润性,肿瘤大小范围4至15 mm,中位9 mm)。
  • 总体补充癌症检出率为每1000名患者23.9例,95%CI 12.0至42.4。
  • 所有癌症均为1或2级、ER+ ERBB2-、淋巴结阴性。
  • CEM筛查显示高特异度0.875(95%CI 0.844至0.906)、高阴性预测值0.998(95%CI 0.993至1.000)、中等阳性预测值1为0.164(95%CI 0.076至0.253)、中等阳性预测值3为0.275(95%CI 0.137至0.413)、高敏感度0.917(95%CI 0.760至1.000)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要在更大规模、多机构、多年的CEM试验中验证。
  • 原文将本研究描述为试点试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) have shown similar diagnostic performance in detection of breast cancer. Limited CEM data are available for high-risk breast cancer screening. The purpose of the study was to prospectively investigate the efficacy of supplemental screening CEM in elevated risk patients. MATERIALS AND METHODS: A prospective, single-institution, institutional review board-approved observational study was conducted in asymptomatic elevated risk women age 35 years or older who had a negative conventional two-dimensional digital breast tomosynthesis screening mammography (MG) and no additional supplemental screening within the prior 12 months. RESULTS: Four hundred sixty women were enrolled from February 2019 to April 2021. The median age was 56.8 (range, 35.0-79.2) years; 408 of 460 (88.7%) were mammographically dense. Biopsy revealed benign changes in 22 women (22/37, 59%), high-risk lesions in four women (4/37, 11%), and breast cancer in 11 women (11/37, 30%). Fourteen cancers (10 invasive, tumor size range 4-15 mm, median 9 mm) were diagnosed in 11 women. The overall supplemental cancer detection rate was 23.9 per 1,000 patients, 95% CI (12.0 to 42.4). All cancers were grade 1 or 2, ER+ ERBB2-, and node negative. CEM imaging screening offered high specificity (0.875 [95% CI, 0.844 to 0.906]), high NPV (0.998 [95% CI, 0.993 to 1.000), moderate PPV1 (0.164 [95% CI, 0.076 to 0.253), moderate PPV3 (0.275 [95% CI, 0.137 to 0.413]), and high sensitivity (0.917 [95% CI, 0.760 to 1.000]). At least 1 year of imaging follow-up was available on all patients, and one interval cancer was detected on breast MRI 4 months after negative screening CEM. CONCLUSION: A pilot trial demonstrates a supplemental cancer detection rate of 23.9 per 1,000 in women at an elevated risk for breast cancer. Larger, multi-institutional, multiyear CEM trials in patients at elevated risk are needed for validation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Patel BK, Carnahan MB, Northfelt D, et al. Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. J Clin Oncol. 2024. PMID: 39058970. doi:10.1200/JCO.22.02819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。